10% OFF Crypto | 3rd Party Tested | FREE Worldwide Shipping $400+ ($750+ for USA)
Menu
Cart
retatrutide 10-40 mg lyophilized vial
edgepeptides retatrutide 30 mg janoshik test
edge peptides retatrutide 20 mg janoshik test
edgepeptides retatrutide 10 mg chromate test
lyophilized peptide vial box (white cap)

Retatrutide 10-40mg | 10 Vial Box

Price range: $500.0 through $1,220.0

Buy retatrutide 10, 20, 30, or 40 mg (one 10-vial box). Worldwide dispatch 7 – 14 days to the USA, UK, CA, AUS & NZ. All orders are shipped wholesale in unbranded packaging.

Bulk discounts
Quantity Bulk Discount Price
210%$450.0
3-515%$425.0
6-1020%$400.0
SKU: RET10 Category:

Description

Retatrutide is a next-generation peptide designed to help manage blood sugar levels and support weight loss by mimicking natural hormones that regulate hunger and glucose. It’s studied for its role in combating obesity and improving blood sugar control in people with type 2 diabetes.

Not for human use; research use only.

Minimum order quantity: one box (10 vials x 10-40 mg, 100-400 mg in total).

Note: Product images show branded labels for illustration purposes only. All peptides are shipped in wholesale, unbranded packaging. You can see an actual example photo of the peptide vials and container above.

Additional information

Purity

≥99.0%
Molar Mass

4731.33
Molecular Formula

C₂₂₇H₃₅₄N₄₈O₆₉
Sequence

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Strength

10MG, 20MG, 30MG, 40MG
  1. Jastreboff, Ania M., et al. "Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial." New England Journal of Medicine 389.6 (2023): 514-526.
  2. Rosenstock, Julio, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet 402.10401 (2023): 529-544.
  3. Doggrell, Sheila A. "Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?." Expert opinion on investigational drugs 32.5 (2023): 355-359.
  4. Urva, Shweta, et al. "The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying." Diabetes, Obesity and Metabolism 25.9 (2023): 2784-2788.
  5. Kaur, Manmeet, and Saurav Misra. "A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity." European Journal of Clinical Pharmacology 80.5 (2024): 669-676.

Retatrutide 10 mg Chromate Test (2025)

Retatrutide CoA

Retatrutide HPLC

Retatrutide 20 mg Janoshik Test (July 2025)

Retatrutide 30 mg Janoshik Test (Oct. 2025)

Related products